FDA批准地诺单抗治疗骨巨细胞瘤

2013-06-15 佚名 医学论坛网

  2013年6月13日,美国食品与药物管理局(FDA)通过优先审查程序批准了地诺单抗用于治疗成人和某些青少年骨巨细胞瘤(GCTB)。   地诺单抗常见的副作用包括关节疼痛,头痛,恶心,乏力,后背痛。最常见的严重副作用为颌骨坏死和骨髓炎。因该药可能伤害胎儿,因此育龄女性在应用时应采取高度有效的避孕措施。 FDA approves Xgeva to treat giant cell tumor

  2013年6月13日,美国食品与药物管理局(FDA)通过优先审查程序批准了地诺单抗用于治疗成人和某些青少年骨巨细胞瘤(GCTB)。

  地诺单抗常见的副作用包括关节疼痛,头痛,恶心,乏力,后背痛。最常见的严重副作用为颌骨坏死和骨髓炎。因该药可能伤害胎儿,因此育龄女性在应用时应采取高度有效的避孕措施。

FDA approves Xgeva to treat giant cell tumor of the bone

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839234, encodeId=fb57183923450, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Oct 21 02:05:00 CST 2013, time=2013-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475754, encodeId=d28114e5754af, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483866, encodeId=bd84148386666, content=<a href='/topic/show?id=0c59101649f2' target=_blank style='color:#2F92EE;'>#骨巨细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101649, encryptionId=0c59101649f2, topicName=骨巨细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64917916239, createdName=12498ca5m85暂无昵称, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502164, encodeId=30f11502164d1, content=<a href='/topic/show?id=021d4821096' target=_blank style='color:#2F92EE;'>#巨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48210, encryptionId=021d4821096, topicName=巨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11759518880, createdName=wwzzly, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=)]
    2013-10-21 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839234, encodeId=fb57183923450, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Oct 21 02:05:00 CST 2013, time=2013-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475754, encodeId=d28114e5754af, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483866, encodeId=bd84148386666, content=<a href='/topic/show?id=0c59101649f2' target=_blank style='color:#2F92EE;'>#骨巨细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101649, encryptionId=0c59101649f2, topicName=骨巨细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64917916239, createdName=12498ca5m85暂无昵称, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502164, encodeId=30f11502164d1, content=<a href='/topic/show?id=021d4821096' target=_blank style='color:#2F92EE;'>#巨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48210, encryptionId=021d4821096, topicName=巨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11759518880, createdName=wwzzly, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839234, encodeId=fb57183923450, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Oct 21 02:05:00 CST 2013, time=2013-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475754, encodeId=d28114e5754af, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483866, encodeId=bd84148386666, content=<a href='/topic/show?id=0c59101649f2' target=_blank style='color:#2F92EE;'>#骨巨细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101649, encryptionId=0c59101649f2, topicName=骨巨细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64917916239, createdName=12498ca5m85暂无昵称, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502164, encodeId=30f11502164d1, content=<a href='/topic/show?id=021d4821096' target=_blank style='color:#2F92EE;'>#巨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48210, encryptionId=021d4821096, topicName=巨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11759518880, createdName=wwzzly, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839234, encodeId=fb57183923450, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Oct 21 02:05:00 CST 2013, time=2013-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475754, encodeId=d28114e5754af, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483866, encodeId=bd84148386666, content=<a href='/topic/show?id=0c59101649f2' target=_blank style='color:#2F92EE;'>#骨巨细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101649, encryptionId=0c59101649f2, topicName=骨巨细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64917916239, createdName=12498ca5m85暂无昵称, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502164, encodeId=30f11502164d1, content=<a href='/topic/show?id=021d4821096' target=_blank style='color:#2F92EE;'>#巨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48210, encryptionId=021d4821096, topicName=巨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11759518880, createdName=wwzzly, createdTime=Mon Jun 17 06:05:00 CST 2013, time=2013-06-17, status=1, ipAttribution=)]
    2013-06-17 wwzzly

相关资讯

FDA重申:罗格列酮并不增加心血管事件风险

有关罗格列酮对心血管事件的事情由来以久,有些研究认为它能明显增加心血管事件的风险,而有些研究则持相反观点。最新FDA再次声明,罗格列酮并不增加心血管事件的风险。有关罗格列酮增加心血管事件的不龙去脉,MedSci这里全面回顾一下:罗格列酮显著增加心血管事件发生--2007年2007年New england journal of Medicine发表了一篇重量级文献Effect of Rosiglit

FDA修改硫酸镁注射液药品标签

  美国食品与药物管理局(FDA)基于“若妊娠女性使用硫酸镁注射液超过5~7天,可能导致发育中胎儿出现低血钙和骨骼问题(包括骨质疏松和骨折)”这一新安全信息,修改硫酸镁注射液药品标签。   硫酸镁注射液被用于预防先兆子痫妊娠女性出现癫痫发作,并治疗子痫妊娠女性的癫痫发作。使用该药物治疗早产是标签外用药。   硫酸镁注射液药品标签新增加内容包括:   ⑴ 妊娠期连续应用该药物治疗早产

FDA限制使用硫酸镁用于预防早产

5月30日,美国食品药品管理局(FDA)建议临床医生,在预防早产时不要对孕妇连续使用硫酸镁超过5至7天,因为这种药物可能会对正在发育的胎儿骨骼有损害。FDA解释说,硫酸镁只被批准用于预防子痫前期的癫痫发作,其用于安胎的超出适应症范围的标签外使用能导致婴儿低钙水平、骨量减少或者骨折。 针对这种药物影响的警示内容已被列入药物标签中,其致畸类别也正由A类改为D类。同时药品标签也被修订,强调注射用硫酸镁

MSD失眠症药物Suvorexant获FDA批准希望大增

5月22日,一个医学专家小组表示,默沙东旗下失眠症试验药物Suvorexant的两个研究剂量中较低剂量者安全有效,使这款药物被美国食品药品管理局(FDA)批准的几率增加。 专家顾问小组被召集起来是帮助FDA决定是否批准这款药物,Suvorexant将成为首个旨在帮助人们入睡和保持睡眠的新类型的镇静剂。 5月20日,FDA内部审评人员发表了一份报告,对这款药物引起第二天嗜睡和不清醒驾驶的可能性表

Am J Psychiatry:FDA关于大剂量西酞普兰警告受质疑

  美国一项研究对美国食品与药物管理局(FDA)“西酞普兰>40mg/d可能导致心律失常”的警告提出质疑。研究表明,与(1~20)mg/d相比,西酞普兰>40mg/d与室性心律失常(校正HR=0.68)、全因死亡(校正HR=0.94)、非心源性死亡(校正HR=0.90)风险较低相关,未发现其增加心源性死亡风险;西酞普兰(21~40)m

FDA批准两种药物治疗黑色素瘤

    5月29日,美国食品和药物管理局批准了Tafinlar(dabrafenib)和Mekinist(trametinib)作为晚期或不可切除黑色素瘤的治疗。    黑色素瘤是皮肤癌中最危险的类型,是皮肤疾病死亡的首要原因。 美国国家癌症研究所预计,2013年美国将有76690人被确诊患黑色素瘤, 而其中9480